{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:28Z","timestamp":1792602928815,"version":"4.5.0"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Neprilysin (NEP), a zinc-dependent membrane-bound metallopeptidase, regulates various bioactive peptides, particularly in kidneys, vascular endothelium, and the central nervous system. NEP\u2019s involvement in metabolizing natriuretic peptides, insulin, and enkephalins makes it a promising target for treating cardiovascular and Alzheimer\u2019s diseases. Several NEP inhibitors, such as sacubitril and omapatrilat, have been approved for clinical use, which inhibit NEP activity to prolong the bioactivity of beneficial peptides, thereby exerting therapeutic effects. However, despite the broad clinical application prospects of NEP inhibitors, they still have specific adverse reactions and side effects, such as hypotension, renal impairment, and a potentially increased risk of Alzheimer\u2019s disease. This manuscript comprehensively reviews the progress on single-target and dual-target NEP inhibitors. Dual-target inhibitors often combine with other therapeutic targets, such as angiotensin receptors, to enhance therapeutic effects and reduce adverse reactions. The article also emphasizes these inhibitors' design strategies, structure-activity relationships (SAR), safety, and clinical performance.<\/jats:p>","DOI":"10.3389\/fphar.2024.1501407","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T04:19:32Z","timestamp":1734927572000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications"],"prefix":"10.3389","volume":"15","author":[{"given":"Xinyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/0026-0495(92)90303-R","article-title":"Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin","volume":"41","author":"Abassi","year":"1992","journal-title":"Metabolism"},{"key":"B2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-08-095167-6.00904-6","article-title":"9.4 industrial applications of asymmetric reduction of C=C bonds","volume-title":"Comprehensive chirality","author":"Ager","year":"2012"},{"key":"B3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/1753-0407.13389","article-title":"Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: controversial points and a promising arena","volume":"15","author":"AlAnazi","year":"2023","journal-title":"J. Diabetes"},{"key":"B144","doi-asserted-by":"publisher","first-page":"e17993","DOI":"10.1111\/jcmm.17993","article-title":"Neprilysin inhibitors and risk of Alzheimer\u2019s disease: A future perspective","volume":"28","author":"Ali","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/00005344-199805000-00005","article-title":"Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men","volume":"31","author":"Andersen","year":"1998","journal-title":"J. Cardiovasc Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1021\/acs.jmedchem.1c01924","article-title":"Probing the requirements for dual angiotensin-converting enzyme C-domain selective\/neprilysin inhibition","volume":"65","author":"Arendse","year":"2022","journal-title":"J. Med. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1124\/pr.118.017129","article-title":"Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure","volume":"71","author":"Arendse","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1097\/MJT.0000000000000836","article-title":"Renin-angiotensin inhibition and outcomes in nursing home residents with heart failure","volume":"27","author":"Arundel","year":"2020","journal-title":"Am. J. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1161\/01.HYP.35.6.1226","article-title":"In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor","volume":"35","author":"Azizi","year":"2000","journal-title":"Hypertension"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/eurheartj\/ehv142","article-title":"Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials","volume":"36","author":"Bavishi","year":"2015","journal-title":"Eur. Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A test in context: neprilysin: function, inhibition, and biomarker","volume":"68","author":"Bayes-Genis","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1111\/j.1523-1755.2004.00982.x","article-title":"Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy","volume":"66","author":"Benigni","year":"2004","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","article-title":"Neprilysin inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions","volume":"8","author":"Bozkurt","year":"2023","journal-title":"JACC Basic Transl. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1111\/jgs.12551","article-title":"Prevalence, awareness, treatment, and control of hypertension in elderly adults with chronic kidney disease: results from the survey of prevalence, awareness, and treatment rates in chronic kidney disease patients with hypertension in China","volume":"61","author":"Cai","year":"2013","journal-title":"J Am. Geriatrics Soc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition \u2014 implications for ARNIs","volume":"14","author":"Campbell","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1046\/j.1523-1755.2001.060002715.x","article-title":"Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats","volume":"60","author":"Cao","year":"2001","journal-title":"Kidney Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41581-021-00461-z","article-title":"The therapeutic potential of apelin in kidney disease","volume":"17","author":"Chapman","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1021\/jm990483l","article-title":"Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities","volume":"43","author":"Chen","year":"2000","journal-title":"J. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1042\/cs0860723","article-title":"Effects of physiological increments in human alpha-atrial natriuretic peptide and human brain natriuretic peptide in normal male subjects","volume":"86","author":"Cheung","year":"1994","journal-title":"Clin. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"H894","DOI":"10.1152\/ajpheart.1987.252.5.H894","article-title":"Atrial natriuretic peptide increases resistance to venous return in rats","volume":"252","author":"Chien","year":"1987","journal-title":"Am. J. Physiology-Heart Circulatory Physiology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5005\/japi-11001-0209","article-title":"The power and promise of angiotensin receptor neprilysin inhibitor (ARNI) in heart failure management: national consensus statement","volume":"71","author":"Chopra","year":"2023","journal-title":"J. Assoc. Physicians India"},{"key":"B21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1146\/annurev.ph.52.030190.003411","article-title":"Renal effects of atrial natriuretic factor","volume":"52","author":"Cogan","year":"1990","journal-title":"Annu. Rev. Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1021\/jm950590p","article-title":"Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors","volume":"39","author":"Coric","year":"1996","journal-title":"J. Med. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.1021\/acs.jmedchem.8b01309","article-title":"Molecular basis for multiple omapatrilat binding sites within the ACE C-domain: implications for drug design","volume":"61","author":"Cozier","year":"2018","journal-title":"J. Med. Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1124\/jpet.112.199307","article-title":"C-type natriuretic peptide protects the retinal pigment epithelium against advanced glycation end product\u2013induced barrier dysfunction","volume":"344","author":"Dahrouj","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2337\/cd21-0090","article-title":"Protecting the kidneys: update on therapies to treat diabetic nephropathy","volume":"40","author":"Davis","year":"2022","journal-title":"Clin. Diabetes"},{"key":"B26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/fcp.12983","article-title":"Angiotensin 1\u20137 increases cardiac tolerance to ischemia\/reperfusion and mitigates adverse remodeling of the heart\u2014the signaling mechanism","volume":"38","author":"Derkachev","year":"2024","journal-title":"Fundamemntal Clin. Pharma"},{"key":"B27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.amjcard.2004.03.074","article-title":"Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure","volume":"94","author":"Dickstein","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0014-5793(97)00681-9","article-title":"Characterisation of neprilysin (EC 3.4.24.11) S 2, subsite","volume":"411","author":"Dion","year":"1997","journal-title":"FEBS Lett."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-24-0636","article-title":"Uptitration of sacubitril\/valsartan and outcomes in patients with heart failure - insight from the REVIEW-HF registry","author":"Doi","year":"2024","journal-title":"Circ. J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"33678","DOI":"10.1038\/srep33678","article-title":"Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney","volume":"6","author":"Domenig","year":"2016","journal-title":"Sci. Rep."},{"key":"B31","first-page":"497","article-title":"Obtaining of measles virus haemagglutinin from strain L-16 grown in primary cell cultures","volume":"19","author":"Dorofeyeva","year":"1975","journal-title":"Acta Virol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fphar.2012.00093","article-title":"A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor Racecadotril","volume":"3","author":"Eberlin","year":"2012","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1161\/01.RES.62.2.191","article-title":"Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor","volume":"62","author":"Edwards","year":"1988","journal-title":"Circ. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"15262","DOI":"10.1074\/jbc.270.25.15262","article-title":"Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum","volume":"270","author":"Emoto","year":"1995","journal-title":"J. Biol. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Epstein","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/19382014.2018.1502521","article-title":"Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner","volume":"10","author":"Esser","year":"2018","journal-title":"Islets"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00125-019-4889-y","article-title":"Neprilysin inhibition: a new therapeutic option for type 2 diabetes?","volume":"62","author":"Esser","year":"2019","journal-title":"Diabetologia"},{"key":"B150","doi-asserted-by":"publisher","first-page":"E307","DOI":"10.1152\/ajpendo.00234.2021","article-title":"Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with \u03b2-cell dysfunction","volume":"322","author":"Esser","year":"2022","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B151","doi-asserted-by":"publisher","first-page":"bqad055","DOI":"10.1210\/endocr\/bqad055","article-title":"Acute inhibition of intestinal neprilysin enhances insulin secretion via GLP-1 receptor signaling in male mice","volume":"164","author":"Esser","year":"2023","journal-title":"Endocrinology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1161\/01.CIR.97.23.2323","article-title":"Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo","volume":"97","author":"Ferro","year":"1998","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.1021\/acs.jmedchem.7b00010","article-title":"Synthetic approaches to the new drugs approved during 2015","volume":"60","author":"Flick","year":"2017","journal-title":"J. Med. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1021\/jm950783c","article-title":"Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action","volume":"39","author":"Fournie-Zaluski","year":"1996","journal-title":"J. Med. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1172\/JCI113141","article-title":"Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man","volume":"80","author":"Fujita","year":"1987","journal-title":"J. Clin. Invest."},{"key":"B42","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/dom.12630","article-title":"Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?","volume":"18","author":"Gallagher","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"B43","doi-asserted-by":"publisher","first-page":"12569","DOI":"10.1021\/bi991043z","article-title":"Crystal structures of alpha-mercaptoacyldipeptides in the thermolysin active site: structural parameters for a Zn monodentation or bidentation in metalloendopeptidases","volume":"38","author":"Gaucher","year":"1999","journal-title":"Biochemistry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"14385","DOI":"10.1038\/s41598-018-32773-9","article-title":"Neprilysin inhibition promotes corneal wound healing","volume":"8","author":"Genova","year":"2018","journal-title":"Sci. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1111\/bph.13946","article-title":"Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes","volume":"174","author":"Goru","year":"2017","journal-title":"Br. J Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000355462","article-title":"Impact of Vitamin D on amyloid precursor protein processing and amyloid-\u03b2 peptide degradation in Alzheimer's disease","volume":"13","author":"Grimm","year":"2014","journal-title":"Neurodegener. Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual\u2010acting angiotensin receptor\u2014neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J. Clin. Pharma"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1172\/JCI115730","article-title":"Atrial natriuretic peptide(31-67) inhibits Na+ transport in rabbit inner medullary collecting duct cells. Role of prostaglandin E2","volume":"89","author":"Gunning","year":"1992","journal-title":"J. Clin. Invest."},{"key":"B149","doi-asserted-by":"publisher","first-page":"bqae058","DOI":"10.1210\/endocr\/bqae058","article-title":"Neprilysin inhibition promotes skeletal growth via the CNP\/NPR-B pathway","volume":"165","author":"Hakata","year":"2024","journal-title":"Endocrinology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10792-012-9651-0","article-title":"Immunohistochemical expression of fas ligand (FasL) and neprilysin (neutral endopeptidase\/CD10) in keratoconus","volume":"33","author":"Hasby","year":"2013","journal-title":"Int. Ophthalmol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1093\/ndt\/gfad038","article-title":"Pharmacokinetics and pharmacodynamics of sacubitril\/valsartan in peritoneal dialysis patients","volume":"38","author":"He","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"B51","doi-asserted-by":"publisher","first-page":"6912","DOI":"10.1021\/bi00527a026","article-title":"Binding of hydroxamic acid inhibitors to crystalline thermolysin suggests a pentacoordinate zinc intermediate in catalysis","volume":"20","author":"Holmes","year":"1981","journal-title":"Biochemistry"},{"key":"B52","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0196-9781(95)00021-b","article-title":"Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism","volume":"16","author":"Howell","year":"1995","journal-title":"Peptides"},{"key":"B53","first-page":"481","article-title":"Enhancement of the antigenic activity and virulence of the vaccine strain E of Rickettsia prow azeki by passages in cell culture","volume":"19","author":"Ignatovich","year":"1975","journal-title":"Acta Virol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"19066","DOI":"10.1074\/jbc.M710509200","article-title":"Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila","volume":"283","author":"Iijima-Ando","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B55","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1523\/JNEUROSCI.4792-03.2004","article-title":"Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain","volume":"24","author":"Iwata","year":"2004","journal-title":"J. Neurosci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1373\/clinchem.2015.243626","article-title":"Unraveling N-terminal pro\u2013B-type natriuretic peptide: another piece to a very complex puzzle in heart failure patients","volume":"61","author":"Jaffe","year":"2015","journal-title":"Clin. Chem."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"B58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1291\/hypres.27.109","article-title":"Relationship between the contents of adrenomedullin and distributions of neutral endopeptidase in blood and tissues of spontaneously hypertensive rats","volume":"27","author":"Jiang","year":"2004","journal-title":"Hypertens. Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US renal data system 2020 annual data report: epidemiology of kidney disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41440-022-00923-2","article-title":"Angiotensin receptor-neprilysin inhibitors for hypertension-hemodynamic effects and relevance to hypertensive heart disease","volume":"45","author":"Kario","year":"2022","journal-title":"Hypertens. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1042\/bj1370477","article-title":"The purification and specificity of a neutral endopeptidase from rabbit kidney brush border","volume":"137","author":"Kerr","year":"","journal-title":"Biochem. J."},{"key":"B62","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1042\/bj1370477","article-title":"The purification and specificity of a neutral endopeptidase from rabbit kidney brush border","volume":"137","author":"Kerr","year":"","journal-title":"Biochem. J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"B64","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1021\/jm960583g","article-title":"Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors","volume":"40","author":"Ksander","year":"","journal-title":"J. Med. Chem."},{"key":"B65","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1021\/jm960582o","article-title":"Ortho-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors","volume":"40","author":"Ksander","year":"","journal-title":"J. Med. Chem."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1021\/jm00010a014","article-title":"Dicarboxylic acid dipeptide neutral endopeptidase inhibitors","volume":"38","author":"Ksander","year":"1995","journal-title":"J. Med. Chem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.peptides.2018.04.011","article-title":"Apelin and Elabela\/Toddler; double ligands for APJ\/Apelin receptor in heart development, physiology, and pathology","volume":"111","author":"Kuba","year":"2019","journal-title":"Peptides"},{"key":"B68","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1107\/S2053230X19006046","article-title":"Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiophen","volume":"75","author":"Labiuk","year":"2019","journal-title":"Acta Crystallogr. F. Struct. Biol. Commun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1002\/mco2.330","article-title":"Novel aspect of neprilysin in kidney fibrosis via ACSL4\u2010mediated ferroptosis of tubular epithelial cells","volume":"4","author":"Lai","year":"2023","journal-title":"MedComm"},{"key":"B70","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0014-2999(93)90371-N","article-title":"Analgesic potency of S-acetylthiorphan after intravenous administration to mice","volume":"243","author":"Lambert","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"175754","DOI":"10.1016\/j.ejphar.2023.175754","article-title":"Sacubitril\/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats","volume":"952","author":"Li","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/mt.2009.115","article-title":"Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer Disease","volume":"17","author":"Liu","year":"2009","journal-title":"Mol. Ther."},{"key":"B148","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mcn.2010.05.014","article-title":"Circulating neprilysin clears brain amyloid","volume":"45","author":"Liu","year":"2010","journal-title":"Mol. Cell. Neurosci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.biopha.2017.04.024","article-title":"Neprilysin inhibitors: a new hope to halt the diabetic cardiovascular and renal complications?","volume":"90","author":"Malek","year":"2017","journal-title":"Biomed. & Pharmacother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2013","journal-title":"Eur. Heart J."},{"key":"B74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol."},{"key":"B75","first-page":"1324","article-title":"Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction","volume":"275","author":"Marie","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B145","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/156720510791050849","article-title":"Diabetes NEP-Like Endopeptidases and Alzheimers Disease","volume":"7","author":"Marr","year":"2010","journal-title":"CAR"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.jacc.2024.08.012","article-title":"Asymptomatic vs symptomatic hypotension with sacubitril\/valsartan in heart failure and reduced ejection fraction in PARADIGM-HF","volume":"84","author":"Matsumoto","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/ajh\/hpz146","article-title":"Angiotensin-(1-7): translational avenues in cardiovascular control","volume":"32","author":"Medina","year":"2019","journal-title":"Am. J. Hypertens."},{"key":"B79","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0167-4781(92)90036-Y","article-title":"Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface","volume":"1131","author":"Misumi","year":"1992","journal-title":"Biochimica Biophysica Acta (BBA) - Gene Struct. Expr."},{"key":"B80","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1254\/jphs.SRJ05001X","article-title":"The kallikrein-kinin system: current and future pharmacological targets","volume":"99","author":"Moreau","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsb.2018.06.004","article-title":"High resolution crystal structure of substrate-free human neprilysin","volume":"204","author":"Moss","year":"2018","journal-title":"J. Struct. Biol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/1873-3468.13602","article-title":"Crystal structure of peptide-bound neprilysin reveals key binding interactions","volume":"594","author":"Moss","year":"2020","journal-title":"FEBS Lett."},{"key":"B83","doi-asserted-by":"publisher","first-page":"26","DOI":"10.29001\/2073-8552-2024-39-3-26-33","article-title":"Angiotensin 1-7 \u2013 a peptide that increases the resistance of the heart to ischemia and reperfusion: narrative review","volume":"39","author":"Mukhomedzyanov","year":"2024","journal-title":"SJCEM"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1172\/JCI115146","article-title":"Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide","volume":"87","author":"Mukoyama","year":"1991","journal-title":"J. Clin. Invest."},{"key":"B85","doi-asserted-by":"publisher","first-page":"111363","DOI":"10.1016\/j.mad.2020.111363","article-title":"Neprilysin expression and functions in development, ageing and disease","volume":"192","author":"Nalivaeva","year":"2020","journal-title":"Mech. Ageing Dev."},{"key":"B86","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0895-7061(99)00009-6","article-title":"Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects","volume":"12","author":"Norton","year":"1999","journal-title":"Am. J. Hypertens."},{"key":"B87","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00004872-199203000-00011","article-title":"Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension","volume":"10","author":"O\u2019Connell","year":"1992","journal-title":"J. Hypertens."},{"key":"B88","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1006\/jmbi.1999.3492","article-title":"Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon","volume":"296","author":"Oefner","year":"","journal-title":"J. Mol. Biol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1006\/jmbi.1999.3492","article-title":"Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon","volume":"296","author":"Oefner","year":"","journal-title":"J. Mol. Biol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1107\/S0907444903027410","article-title":"Structural analysis of neprilysin with various specific and potent inhibitors","volume":"60","author":"Oefner","year":"2004","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"B91","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes & Endocrinol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1369\/0022155418765164","article-title":"Neprilysin deficiency is associated with expansion of islet \u03b2-cell mass in high fat-fed mice","volume":"66","author":"Parilla","year":"2018","journal-title":"J. Histochem Cytochem"},{"key":"B93","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S2213-8587(13)70029-9","article-title":"Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial","volume":"1","author":"Parvanova","year":"2013","journal-title":"Lancet Diabetes & Endocrinol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"602363","DOI":"10.3389\/fcvm.2020.602363","article-title":"Hospitalization and mortality in patients with heart failure treated with sacubitril\/valsartan vs. Enalapril: a real-world, population-based study","volume":"7","author":"Pathadka","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0022-2836(88)90623-7","article-title":"Crystal structure of neutral protease from Bacillus cereus refined at 3.0A\u02daresolution and comparison with the homologous but more thermostable enzyme thermolysin","volume":"199","author":"Pauptit","year":"1988","journal-title":"J. Mol. Biol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"848","DOI":"10.4049\/jimmunol.0903878","article-title":"Substance P is a key mediator of stress-induced protection from allergic sensitization via modified antigen presentation","volume":"186","author":"Pavlovic","year":"2011","journal-title":"J. Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.15420\/cfr.2019.21","article-title":"Neprilysin as a biomarker: challenges and opportunities","volume":"6","author":"Pavo","year":"2020","journal-title":"Card. Fail Rev."},{"key":"B146","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sc.2013.106","article-title":"Local non-viral gene delivery of apoptin delays the onset of paresis in an experimental model of intramedullary spinal cord tumor","volume":"52","author":"Pennant","year":"2014","journal-title":"Spinal Cord"},{"key":"B98","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.nbd.2006.08.003","article-title":"Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit","volume":"24","author":"Poirier","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"B99","first-page":"449","article-title":"Effect of adsorbents on IgM and IgG measles antibodies","volume":"19","author":"Polna","year":"1975","journal-title":"Acta Virol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"B101","doi-asserted-by":"publisher","first-page":"6722","DOI":"10.1167\/iovs.16-20289","article-title":"Beneficial effects of combined at 1 receptor\/neprilysin inhibition (ARNI) versus at 1 receptor blockade alone in the diabetic eye","volume":"57","author":"Prasad","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B102","first-page":"467","article-title":"Distribution of Lednice (Yaba 1) virus in the chick embryo","volume":"19","author":"Rajc\u00e1ni","year":"1975","journal-title":"Acta Virol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11897-017-0327-y","article-title":"Potential expanded indications for neprilysin inhibitors","volume":"14","author":"Riddell","year":"2017","journal-title":"Curr. Heart Fail Rep."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1021\/jm970041e","article-title":"Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase","volume":"40","author":"Robl","year":"1997","journal-title":"J. Med. Chem."},{"key":"B105","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/288286a0","article-title":"The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice","volume":"288","author":"Roques","year":"1980","journal-title":"Nature"},{"key":"B106","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/00004872-199917030-00017","article-title":"Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100 240, on endocrine and renal functions in healthy volunteers","volume":"17","author":"Rousso","year":"1999","journal-title":"J. Hypertens."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41598-020-80877-y","article-title":"Incidence of cardiovascular events and mortality in Korean patients with chronic kidney disease","volume":"11","author":"Ryu","year":"2021","journal-title":"Sci. Rep."},{"key":"B109","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/hlca.200590051","article-title":"Second\u2010generation inhibitors for the metalloprotease neprilysin based on bicyclic heteroaromatic scaffolds: synthesis, biological activity, and X\u2010ray crystal\u2010structure analysis","volume":"88","author":"Sahli","year":"2005","journal-title":"Helvetica Chim. Acta"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e0189526","DOI":"10.1371\/journal.pone.0189526","article-title":"Profound loss of neprilysin accompanied by decreased levels of neuropeptides and increased CRP in ulcerative colitis","volume":"12","author":"Sarg\u0131n","year":"2017","journal-title":"PLoS ONE"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart\u00a0Failure drug treatment-Inertia,\u00a0Titration, and discontinuation: a multinational observational study (evolution HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail."},{"key":"B112","doi-asserted-by":"publisher","first-page":"27909","DOI":"10.1038\/srep27909","article-title":"Structure of neprilysin in complex with the active metabolite of sacubitril","volume":"6","author":"Schiering","year":"2016","journal-title":"Sci. Rep."},{"key":"B113","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0924-8579(99)00151-X","article-title":"Racecadotril: a new approach to the treatment of diarrhoea","volume":"14","author":"Schwartz","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B114","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.lfs.2012.03.022","article-title":"The dual endothelin converting enzyme\/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans","volume":"91","author":"Seed","year":"2012","journal-title":"Life Sci."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur. J. Heart Fail"},{"key":"B116","doi-asserted-by":"publisher","first-page":"5488","DOI":"10.1021\/acs.jmedchem.0c00441","article-title":"Molecular basis for omapatrilat and sampatrilat binding to neprilysin\u2014implications for dual inhibitor design with angiotensin-converting enzyme","volume":"63","author":"Sharma","year":"2020","journal-title":"J. Med. Chem."},{"key":"B117","doi-asserted-by":"publisher","first-page":"00282","DOI":"10.1016\/j.ahj.2024.10.020","article-title":"Win ratio analyses using a modified hierarchical composite outcome: insights from PARAGLIDE-HF","author":"Shoji","year":"2024","journal-title":"Am. Heart J."},{"key":"B118","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0196-9781(84)90020-2","article-title":"Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase","volume":"5","author":"Skidgel","year":"1984","journal-title":"Peptides"},{"key":"B119","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2337\/db23-0848","article-title":"In vivo inhibition of dipeptidyl peptidase 4 allows measurement of GLP-1 secretion in mice","volume":"73","author":"Smits","year":"2024","journal-title":"Diabetes"},{"key":"B120","first-page":"259","article-title":"The micro-organisms of tsetse flies","volume":"32","author":"Southwood","year":"1975","journal-title":"Acta Trop."},{"key":"B121","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1046\/j.1365-2362.1997.1070653.x","article-title":"Responses of atrial natriuretic peptide and brain natriuretic peptide to exercise in patients with chronic heart failure and normal control subjects","volume":"27","author":"Steele","year":"1997","journal-title":"Eur. J. Clin. Investig."},{"key":"B122","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1042\/bj2430183","article-title":"The hydrolysis of \u03b1 -human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11","volume":"243","author":"Stephenson","year":"1987","journal-title":"Biochem. J."},{"key":"B123","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrd4615","article-title":"From silos to systems: an integrated approach to neuroscience innovation","volume":"14","author":"Stuss","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1681\/ASN.V12102051","article-title":"Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone","volume":"12","author":"Taal","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ekir.2023.10.006","article-title":"Updates on new therapies for patients with CKD","volume":"9","author":"Tarun","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"B126","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.npep.2007.05.002","article-title":"Substance P receptor expression in patients with inflammatory bowel disease. Determination by three different techniques, i.e., storage phosphor autoradiography, RT-PCR and immunohistochemistry","volume":"41","author":"Ter Beek","year":"2007","journal-title":"Neuropeptides"},{"key":"B127","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/protein\/12.2.141","article-title":"A three-dimensional construction of the active site (region 507\u2013749) of human neutral endopeptidase (EC.3.4.24.11)","volume":"12","author":"Tiraboschi","year":"1999","journal-title":"Protein Eng. Des. Sel."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.7326\/M21-0834","article-title":"Management of blood pressure in patients with chronic kidney disease not receiving dialysis: synopsis of the 2021 KDIGO clinical practice guideline","volume":"174","author":"Tomson","year":"2021","journal-title":"Ann. Intern Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"R915","DOI":"10.1152\/ajpregu.1987.252.5.R915","article-title":"Atrial natriuretic factor decreases whole-body capillary absorption in rats","volume":"252","author":"Trippodo","year":"1987","journal-title":"Am. J. Physiology-Regulatory, Integr. Comp. Physiology"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e029565","DOI":"10.1161\/JAHA.122.029565","article-title":"Updates for cardio-kidney protective effects by angiotensin receptor-neprilysin inhibitor: requirement for additional evidence of kidney protection","volume":"12","author":"Tsukamoto","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"B131","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction \u2015 results from the PARALLEL-HF study","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ. J."},{"key":"B132","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K","article-title":"The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function","volume":"23","author":"Turner","year":"2001","journal-title":"Bioessays"},{"key":"B133","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0731-7085(97)00127-1","article-title":"Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA)","volume":"16","author":"Venn","year":"","journal-title":"J. Pharm. Biomed. Analysis"},{"key":"B134","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0731-7085(97)00126-X","article-title":"Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol","volume":"16","author":"Venn","year":"","journal-title":"J. Pharm. Biomed. Analysis"},{"key":"B135","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12031-013-0205-3","article-title":"Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-Induced colitis in mice","volume":"52","author":"Vu","year":"2014","journal-title":"J. Mol. Neurosci."},{"key":"B136","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0009-9236(98)90075-3","article-title":"Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension","volume":"64","author":"Wallis","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"B137","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1476-5381.1992.tb14462.x","article-title":"Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C\u2010ANP receptor ligand in the rat","volume":"107","author":"Wilkins","year":"1992","journal-title":"Br. J Pharmacol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00125-016-4172-4","article-title":"Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels","volume":"60","author":"Willard","year":"2017","journal-title":"Diabetologia"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41440-021-00706-1","article-title":"Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment","volume":"44","author":"Yamamoto","year":"2021","journal-title":"Hypertens. Res."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/0024-3205(86)90137-2","article-title":"Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man","volume":"38","author":"Yandle","year":"1986","journal-title":"Life Sci."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1179573520907397","DOI":"10.1177\/1179573520907397","article-title":"Current and future treatments in alzheimer disease: an update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"B142","doi-asserted-by":"publisher","first-page":"e011860","DOI":"10.1161\/CIRCHEARTFAILURE.124.011860","article-title":"Analysis of the PARAGON-HF study results using win ratio","volume":"17","author":"Yoon","year":"2024","journal-title":"Circ. Heart Fail"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/db11-1593","article-title":"Neprilysin deficiency protects against fat-induced insulin secretory dysfunction by maintaining calcium influx","volume":"62","author":"Zraika","year":"2013","journal-title":"Diabetes"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1501407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T04:19:45Z","timestamp":1734927585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1501407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":151,"alternative-id":["10.3389\/fphar.2024.1501407"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1501407","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"article-number":"1501407"}}